A5037925743- Acute Myeloid Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Platelet Disorders and Treatments
- CAR-T cell therapy research
- Acute Lymphoblastic Leukemia research
- Hematopoietic Stem Cell Transplantation
- Extracellular vesicles in disease
- Monoclonal and Polyclonal Antibodies Research
- Chronic Lymphocytic Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Lung Cancer Treatments and Mutations
- Blood Coagulation and Thrombosis Mechanisms
- Lymphoma Diagnosis and Treatment
- Multiple Myeloma Research and Treatments
- Hemophilia Treatment and Research
- RNA modifications and cancer
- Immunotherapy and Immune Responses
- Medical Imaging and Pathology Studies
- Cancer Genomics and Diagnostics
- Colorectal Cancer Treatments and Studies
- Blood properties and coagulation
- Immunodeficiency and Autoimmune Disorders
- Molecular Biology Techniques and Applications
- Cancer Cells and Metastasis
- Cancer Diagnosis and Treatment
Klinikum Braunschweig
2018-2024
Medizinische Hochschule Hannover
2005-2016
Jagiellonian University
2014
University Medical Center
2014
Pohang University of Science and Technology
2014
AGH University of Krakow
2014
Allgemeines Krankenhaus Celle
2006
Abstract Motivation: Extracellular vesicles (EVs) are spherical bilayered proteolipids, harboring various bioactive molecules. Due to the complexity of vesicular nomenclatures and components, online searches for EV-related publications components currently challenging. Results: We present an improved version EVpedia, a public database EVs research. This community web portal contains identification orthologous bioinformatic tools personalized function. EVpedia includes 6879 publications, 172...
The antibody-drug conjugate polatuzumab vedotin (pola) has recently been approved in combination with bendamustine and rituximab (pola-BR) for patients refractory or relapsed (r/r) large B-cell lymphoma (LBCL). To investigate the efficacy of pola-BR a real-world setting, we retrospectively analyzed 105 LBCL who were treated 26 German centers under national compassionate use program. Fifty-four received pola as salvage treatment 51 intention to bridge chimeric antigen receptor (CAR) T-cell...
BackgroundSotorasib is a first-in-class KRAS p.G12C-inhibitor that has entered clinical trials in pretreated patients with non-small cell lung cancer (NSCLC) 2018. First response rates were promising the CodeBreaK trials. It remains unclear whether to sotorasib and outcomes differ real-world setting when including underrepresented trials.MethodsPatients p.G12C-mutated advanced or metastatic NSCLC received within German multicenter compassionate use program between 2020 2022. Data on...
The combination of cytoreductive chemotherapy with reduced-intensity conditioning (RIC) is a highly effective antileukemic therapy. Purpose this retrospective analysis was to evaluate the efficacy and toxicity clofarabine-based followed by RIC allogeneic stem cell transplantation (SCT) for high-risk, relapsed, or refractory acute myeloid leukemia (AML) myelodysplastic syndromes (MDS). From May 2007 until October 2009, total 27 patients underwent SCT after treatment clofarabine ara-C 5d (4Gy...
Consent regarding the correct processing and storage of blood microparticles is lacking different protocols for freeze-thaw cycle exist. Therefore, three thawing procedures were evaluated their influence on recovery composition microparticles. Microparticles prepared by TRAP-6 or A23187 stimulation platelet-rich plasma from smokers nonsmokers (n = 8), an endothelial cell line directly obtained platelet-free septic patients 5). After snap-freezing in liquid nitrogen samples thawed at 37...
We present the case of a 64-year-old man diagnosed with large B-cell lymphoma who relapsed twice after standard-of-care therapy. Due to persisting cytopenia, Next generation sequencing analysis was performed, revealing small TP53-mutated clone. As third-line therapy, patient treated CAR-T cells, which resulted in complete remission. However, this treatment also led expansion clone and therapy-related myelodysplasia complex aberrant karyotype. This may serve as paradigmatic example clonal...
Monitoring of the global haemostatic capacity is desired to optimize treatment with bypassing agents in inhibitor patients. Thrombelastographic methods have been used ex vivo studies and were suggested useful evaluate individual response agents. This study aimed at assessing changes thrombelastographic profiles their association clinical outcome patients treated recombinant factor VIIa (rFVIIa). Ten acquired haemophilia rFVIIa for acute bleeding. Thrombelastography was performed after...
Chronic lung allograft dysfunction (CLAD) is the major outcome limitation for transplant recipients (LTR) after first year, and therapies targeting immunological pathways show only limited success. Because microvesicles (MV) are biomarkers of endothelial coagulation but also involved in responses, we hypothesized that MV, found bronchoalveolar lavage (BAL) fluids (BALF) LTR at CLAD diagnosis, elevated potential prognostic biomarkers.The BALF was collected from 37 time point diagnosis without...
Dyskeratosis congenita (DKC) is associated with impaired telomere maintenance and clinical features of premature aging. In this study, we analysed global DNA methylation (DNAm) profiles DKC patients. Age-associated DNAm changes were not generally accelerated in DKC, but there significant differences to patterns healthy controls, particularly CpG sites related an internal promoter region PR domain containing 8 (PRDM8). Notably, the same genomic was also hypermethylated aplastic anemia (AA) -...
Summary Development of inhibitory antibodies against factor VIII (FVIII) is a severe complication replacement therapy in haemophilia A. Patients with inhibitors are treated high FVIII doses the context immune tolerance (ITT). Data from A mouse model suggest that concentrations prevent formation antibody secreting cells (ASCs) memory B (MBCs) by inducing apoptosis. Fc gamma receptor 2B (CD32) an important regulator cell function, mediating signals after cross-linking receptor. Here, role CD32...
Xenogenic activation of hemostasis (XAH) represents a major hurdle for the transplantation discordant animal organs into humans as it results in thrombotic microangiopathy (TMA). We have previously shown that recombinant human-activated protein C (rhAPC) mitigates XAH and TMA an ex vivo model pig-to-human kidney transplantation. However, use rhAPC may not be feasible perioperative setting due to possible bleeding complications.Here, we explored effects another natural inhibitor coagulation,...
Summary Effects of desmopressin ( DDAVP ) in platelet disorders and primary haemostasis cannot be attributed solely to the increase FVIII / VWF (von Willebrand factor), as concentrates have no effect these circumstances. Microparticles MP can support by expression phospholipids, tissue factor on their surface. We hypothesized that significant amounts are bound after administration consequently depletion should influence :Ag : RC o plasma levels. Platelet‐poor was either obtained well from...
Background. There is compelling evidence that blood-borne tissue factor predominantly found on circulating microparticles (MPs) plays an important role in both, cancer biology and organ stem-cell transplantation (SCT). Therefore, we hypothesized numbers of bearing MPs might be associated with complications outcome allogeneic SCT (allo-SCT). Materials Methods. In a prospective study, enumerated total, platelet, endothelial, plasma samples obtained from up to 60 patients hematologic diseases...
Detection of residual tumor cells in BM and PBPC products has been correlated with worse outcome breast cancer patients. Still, there is a considerable demand for studies investigating the influence actual cell number on prognosis, as quantification routinely cumbersome time consuming and, thus, was evaded. We developed evaluated competitive RT-PCR-ELISA assay cytokeratin 19 (CK19) standard curve that allows multiple samples within working day; mRNA isolation, RT-PCR reaction, automated...